Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation
Oslo, 12August2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its second quarter 2022 results on Friday 19 August2022.
The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 09:00 CET on Friday 19 August 2022. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.
The report and presentation will be available on the company website from 08:00 CET the same day.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 906 86815
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
International Petroleum Corporation Announces First Quarter 2024 Financial and Operational Results7.5.2024 07:30:00 CEST | Press release
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operational results and related management’s discussion and analysis (MD&A) for the three months ended March 31, 2024. William Lundin, IPC's President and Chief Executive Officer, comments: “We are pleased to announce another strong quarter of production and operational performance, which was combined with favourable commodity prices. IPC achieved an average net daily production during the quarter of 48,800 barrels of oil equivalent per day (boepd). Our financial results during the quarter are in line with the 2024 guidance announced at our Capital Markets Day in February as we continue to excel operationally across our operations in Canada, Malaysia and France. At the same time, we also continued with purchases of IPC common shares under the normal course issuer bid, having completed approximately one-third of the current 2023/2024 program between December 2023 a
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 20257.5.2024 07:30:00 CEST | Press release
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS 7 May 2024 at 08.30 EEST Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 Olli Huotari, Senior Vice President responsible for Corporate Functions organization (including, i.a., Communications, Compliance, Corporate Responsibility, Intellectual Property Rights, Legal Affairs and Public Affairs) of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group has informed the company of his decision to leave Orion. Orion will start a recruiting process of the successor to Olli Huotari. In order to secure a proper transition of responsibilities to his successor, Orion and Huotari have agreed that Huotari will continue in his current positions at Orion (including the membership of the Executive Management Board of the Orion Group) until 31 May 2025, after which he will leave the company. Olli
Coloplast styrker stomiporteføljen med tre nye produktlanceringer7.5.2024 07:04:13 CEST | pressemeddelelse
Selskabet har fået refusionsgodkendelse i Storbritannien for Heylo™, verdens første digitale notifikationssystem til at opdage lækage, og udvider samtidig sin SenSura® Mio-produktserie med to nye lanceringer. Da vi lancerede vores 2025-strategi, Strive25, satte vi et klart mål om at hæve behandlingsstandarden for vores brugere og bringe nye produkter hurtigere til markedet. Jeg glæder mig over at se, at vores innovationsteam bliver ved med at levere, senest med lanceringen af disse tre nye stomiprodukter, fortæller Coloplasts innovationsdirektør Nicolai Buhl. Introducerer Heylo For mange mennesker, som lever med stomi, udgør lækage en betydelig fysisk og mental udfordring i deres dagligdag. Heylo er udviklet til at opdage potentiel lækage under basispladen, og ved at advare brugeren tidligt får denne muligheden for at handle og forhindre, at lækagen spreder sig. Produktet består af et sensorlag, der sættes på basispladen, og en ’transmitter’, som er fastgjort til sensorlaget og er forb
Coloplast strengthens ostomy care portfolio with three significant product launches7.5.2024 07:04:13 CEST | Press release
The company has received reimbursement approval in the UK for Heylo™, the world’s first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products. As part of our 2025 strategy, Strive25, we set an ambition to significantly raise the standard of care for our users and bring new products to market at a higher pace. I am excited to see that our Innovation unit continues to deliver on this commitment, latest with these three new products in Ostomy Care, says Executive Vice President of Innovation, Nicolai Buhl. Introducing Heylo For many people living with a stoma, leakage is a significant physical and mental challenge in their daily life. Heylo is designed to detect potential leakages under the ostomy baseplate, and by notifying users at an early stage it enables them to take action and prevent the leakage from progressing. The product consists of a sensor layer that is attached to the baseplate, a transmitter that is attached to the sensor layer
Coloplast A/S - Selskabsmeddelelse nr. 02/2024 - Regnskabsmeddelelse, 1. halvår 2023/247.5.2024 07:00:41 CEST | pressemeddelelse
H1 2023/24 Regnskabsmeddelelse, 1. halvår 2023/24 1. oktober 2023 – 31. marts 2024 Coloplast leverede et solidt 2. kvartal med 8% organisk vækst og en overskudsgrad1) på 27%. Den rapporterede omsætning målt i danske kroner steg 9% med 4 procentpoint bidrag fra Kerecis (underliggende vækst på ca. 35%), delvist udlignet af valutaer. Den organiske vækst pr. forretningsområde var 7% i Stomi, 8% i Kontinens, 13% i Stemme og Respiratorisk Pleje, 8% i Avanceret Sårpleje (8% i Avancerede Sårbandager) og 5% i Urologi.Fortsat godt momentum i den kroniske forretning. Væksten i Stomi var drevet af bredt baseret vækst i Øvrige markeder og Europa, som kompenserede for lavere momentum i USA, hvor væksten var påvirket af ordre-timing og nu forventes at bedres i 2. halvår. Væksten i kontinensforretningen var drevet af porteføljen af intermitterende katetre inklusiv godt bidrag fra Luja™. Stemme og Respiratorisk Pleje leverede et stærkt 2. kvartal drevet af tocifret vækst i både Laryngektomi og Trakeost